Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T-cell responses in a murine acute myeloid leukemia model
暂无分享,去创建一个
M. Bhasin | B. Ebert | G. Freeman | M. Capelletti | D. Kufe | R. Stone | D. Avigan | J. Rosenblatt | M. Weinstock | G. Cheloni | D. Stroopinsky | Jessica J. Liegel | Shira Orr | Beena E. Thomas | K. Mahoney | Adam Morin | M. Nahas | Swati S. Bhasin | Cansu Tacettin | Daniela Torres | Lina Bisharat | M. Rahimian | Haider Ghiasuddin | Ruchit Panchal | Myrna R Nahas | G. Freeman
[1] G. Kochan,et al. Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy , 2019, EMBO molecular medicine.
[2] J. Clohessy,et al. Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy , 2019, Cell Research.
[3] A. Goldberg,et al. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets , 2019, Current Oncology Reports.
[4] F. Slack,et al. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine , 2019, British journal of haematology.
[5] Lai Guan Ng,et al. Dimensionality reduction for visualizing single-cell data using UMAP , 2018, Nature Biotechnology.
[6] P. Sharma,et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. , 2018, Cancer discovery.
[7] Paul Hoffman,et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.
[8] A. Levine,et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy , 2017, Nature.
[9] Shao-Cong Sun,et al. NF-κB signaling in inflammation , 2017, Signal Transduction and Targeted Therapy.
[10] D. Neuberg,et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions , 2016, Science Translational Medicine.
[11] F. Ramos,et al. Acute myeloid leukemia in the older adults , 2016, Leukemia research reports.
[12] H. Zarour. Reversing T-cell Dysfunction and Exhaustion in Cancer , 2016, Clinical Cancer Research.
[13] K. Akashi,et al. A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression. , 2015, Cell stem cell.
[14] G. Freeman,et al. Combination cancer immunotherapy and new immunomodulatory targets , 2015, Nature Reviews Drug Discovery.
[15] T. Whiteside,et al. Programmed death-1 checkpoint blockade in acute myeloid leukemia , 2015, Expert opinion on biological therapy.
[16] Mikhail Shugay,et al. MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.
[17] A. Regev,et al. Spatial reconstruction of single-cell gene expression data , 2015 .
[18] M. Guindani,et al. A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy , 2014, Oncotarget.
[19] Loise M. Francisco,et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance , 2014, The Journal of experimental medicine.
[20] R. Champlin. Reduced intensity allogeneic hematopoietic transplantation is an established standard of care for treatment of older patients with acute myeloid leukemia. , 2013, Best practice & research. Clinical haematology.
[21] Nikhil C. Munshi,et al. Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients , 2013, Clinical Cancer Research.
[22] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[23] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[24] D. Munn,et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.
[25] N. Munshi,et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. , 2011, Blood.
[26] H. Waldmann,et al. mTOR signalling and metabolic regulation of T cell differentiation. , 2010, Current opinion in immunology.
[27] Jenna M. Sullivan,et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.
[28] P. Rotwein,et al. Molecular biology, genetics and biochemistry of the repulsive guidance molecule family. , 2009, The Biochemical journal.
[29] R. Ahmed,et al. mTOR regulates memory CD8 T cell differentiation , 2009, Nature.
[30] S. L. Petersen. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2007, Danish medical bulletin.
[31] Marie-Paule Lefranc,et al. IMGT , the international ImMunoGeneTics information system , 2003 .
[32] J. Allison,et al. ICOS co-stimulatory receptor is essential for T-cell activation and function , 2001, Nature.
[33] G. Peoples,et al. Arming the Immune System Through Vaccination to Prevent Cancer Recurrence. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.